What is OKYO Pharma?
OKYO Pharma operates as a specialized biopharmaceutical enterprise dedicated to the research and development of novel therapeutics. The company focuses primarily on addressing the unmet medical needs of patients suffering from inflammatory eye diseases and chronic ocular pain. By maintaining a rigorous scientific approach, OKYO Pharma aims to translate complex biological insights into viable clinical solutions. Their market position is defined by a strategic focus on high-barrier-to-entry therapeutic areas, where the demand for effective, non-invasive treatments remains high. The firm's operational base in the United Kingdom provides a strategic nexus for international clinical trials and regulatory engagement, positioning them as a key player in the global ophthalmology sector.
How much funding has OKYO Pharma raised?
OKYO Pharma has raised a total of $5.8M across 3 funding rounds:
Stock Offering
$2.5M
Other Financing Round
$1.4M
Other Financing Round
$1.9M
Stock Issuance/Offering (2022): $2.5M, investors not publicly disclosed
Other Financing Round (2025): $1.4M, investors not publicly disclosed
Other Financing Round (2025): $1.9M, investors not publicly disclosed
Key Investors in OKYO Pharma
Undisclosed Investor
An undisclosed investor participating in the funding round, typically focused on long-term capital appreciation within the healthcare and life sciences sectors.
Undisclosed Investor
An undisclosed investor participating in the funding round, representing institutional interests in high-growth biopharmaceutical ventures.
Undisclosed Investor
An undisclosed investor participating in the funding round, specializing in early-to-mid stage biotech financing and strategic asset development.
What's next for OKYO Pharma?
With the successful closure of this recent financing round, OKYO Pharma is well-positioned to accelerate its core research initiatives and expand its clinical trial infrastructure. The capital allocation will likely prioritize the advancement of lead candidates through critical regulatory phases, ensuring that the company maintains its momentum in the ocular therapeutics market. Looking ahead, the firm is expected to focus on scaling its operational capabilities and potentially exploring strategic partnerships to enhance its commercialization strategy. As the company transitions into its next phase of development, the emphasis will remain on achieving key clinical endpoints that validate its proprietary technology and drive long-term value for stakeholders in the life sciences ecosystem.
See full OKYO Pharma company page
